LobbyingData.com Logo

Incyte Corporation (INCY) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.


Discover Incyte Corporation’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.


Using our intelligently designed and intuitive dataset, you can quickly understand how Incyte Corporation (INCY) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Incyte Corporation (INCY) lobbying for?

Summary of Lobbying Data:

– Lobbying Firms: W Strategies, Avenue Solutions, Llc, Incyte Corporation, Tiber Creek Group
– General Issues: Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Medicare/Medicaid, Health Issues
– Specific Issues: Expanding premium and co-pay assistance on prescription drugs for low-income individuals, Subtitle J, H.R.5376 – Implementation of Inflation Reduction Act., Education around innovative therapies in dermatology, H.R.4373 – Further Additional Continuing Appropriations and Extensions Act, The Advanced Research Project Agency-Health (ARPA-H) Act, Issues related to the White House Cancer Moonshot initiative, Issues related to the FY 2023 President’s Budget, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, Affordable Insulin Now Act, Issues related to reauthorization of FDA user fee bills (H.R. 7667), including accelerated approval and reimportation, Issues related to the Public Health Emergency, Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs, S. 3700/H.R. 6833, creating a new inflation rebate under Medicare, capping Medicare Part D premium growth, Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169), issues relating to Medicare Part D and Part B Pricing Reform, H.R.1304 – American Innovation and R&D Competitiveness Act of 2021, and issues related to intellectual property.
– Government Agencies: Senate, House of Representatives

One could infer that the Incyte Corporation is lobbying on these issues to influence government policies that affect their business interests, especially those related to drug pricing, reimbursement, and innovation. They are likely advocating for policies that benefit their products and services, while opposing policies that can limit their profitability or competitiveness. The company seems to be focused on issues related to Medicare and Medicaid, as well as on patent protection and intellectual property rights. They may also be interested in influencing regulatory processes or securing government funding for their research and development initiatives.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore